CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 183 enrolled
Drug / intervention
ASP8062 +1 moredrug
Likely dose
ASP8062 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03092726
NCT03092726Phase 2Completed
CompareCT.gov

A Phase 2a, Randomized, Double-Blind Placebo-controlled, Parallel-group Study to Assess the Analgesic Efficacy and Safety of ASP8062 in Subjects With Fibromyalgia

Astellas Pharma Global Development, Inc.·interventional·Posted Mar 28, 2017·Updated Nov 3, 2025

In Brief

A Phase 2 clinical trial evaluating ASP8062 and Placebo for Fibromyalgia. Completed, enrolled 183 participants across 24 sites.

Detailed Summary

The purpose of this study was to assess analgesic efficacy of ASP8062 relative to placebo as well as the safety and tolerability. This study also assessed the treatment differences in physical function as well the improvements in overall subject status (e.g., fibromyalgia symptoms, global functioning) of ASP8062 relative to placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFibromyalgia
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedMar 28, 2017
Enrollment StartMay 8, 2017
Primary CompletionMar 6, 2018
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 9.3 years ago

Interventions

ASP8062drug

ASP8062 30 mg was administered orally as a single daily dose, taken preferably in the morning with or without food.

Placebodrug

Placebo was administered orally as a single daily dose, taken preferably in the morning with or without food.